Treatment of Bordetella parapertussis in Pediatrics
Treat Bordetella parapertussis in children with the same macrolide antibiotics used for pertussis: azithromycin is the first-line agent across all pediatric age groups.
Recommended Antibiotic Regimens
While the provided evidence focuses on B. pertussis treatment guidelines, B. parapertussis responds to the same macrolide antibiotics based on in vitro susceptibility and clinical practice 1. The CDC pertussis guidelines provide the framework:
Azithromycin (First-Line Agent)
- Infants <6 months: 10 mg/kg per day for 5 days 1
- Children ≥6 months: 10 mg/kg (max 500 mg) on day 1, then 5 mg/kg per day (max 250 mg) on days 2-5 1
Azithromycin is preferred because:
- Shorter treatment course (5 days vs 14 days)
- Once-daily dosing improves adherence
- Better tolerability with fewer GI side effects
- Lower risk of infantile hypertrophic pyloric stenosis (IHPS) in neonates 1
Alternative: Erythromycin
- Infants <1 month: NOT preferred due to IHPS risk; use azithromycin 1
- Infants >1 month and children: 40-50 mg/kg per day (max 2 g/day) in 4 divided doses for 14 days 1
Alternative: TMP-SMZ (For Macrolide Intolerance)
- Contraindicated in infants <2 months (kernicterus risk) 1
- Children ≥2 months: TMP 8 mg/kg/day + SMX 40 mg/kg/day in 2 divided doses for 14 days 1
Clinical Context: When to Treat
Recent evidence shows B. parapertussis causes pertussis-like illness that is often milder but can still be significant 2, 3:
Key clinical features:
- More frequently presents with fever compared to B. pertussis 2
- Paroxysmal cough, vomiting, and apnea can occur
- Classical "whoop" and cyanosis are uncommon 2
- Hospitalization rates can be substantial (72% in one series) 2
Treatment benefits:
- Prompt treatment (within 0-6 days of cough onset) significantly shortens illness duration (10 vs 19 days median) 3
- Early treatment of index cases reduces transmission to household contacts 3
Important Caveats
Monitor for IHPS in young infants:
- Any infant <1 month receiving macrolides requires monitoring for pyloric stenosis 1
- Erythromycin carries highest risk; azithromycin has not been associated with IHPS to date 1
Drug interactions to avoid:
- Do not give azithromycin with aluminum/magnesium antacids simultaneously 1
- Erythromycin and clarithromycin should not be given with astemizole, cisapride, pimozide, or terfenadine 1
Antibiotic considerations:
- Some children with B. parapertussis recover without antibiotics, particularly afebrile cases 2
- However, treatment is warranted to shorten illness duration and prevent transmission 3
- Antibiotics are most effective when started early in the illness course 3
Household prophylaxis:
- Consider prophylaxis for household contacts using same dosing regimens
- Prompt prophylaxis significantly reduces secondary illnesses (RR 0.16) 3
- Prioritize prophylaxis for households with infants <12 months 1
The evidence demonstrates that while B. parapertussis may cause milder disease than B. pertussis in some cases, it still warrants antibiotic treatment to reduce morbidity and transmission, using the same macrolide regimens established for pertussis 1, 3, 4.